MedKoo Cat#: 128814 | Name: SR 2640
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR 2640 is a potent and selective competitive leukotriene D4 and E4 receptor antagonist. SR 2640 inhibits LTD4- but not histamine-induced guinea pig ileum and trachea contraction (pA2 = 8.7).

Chemical Structure

SR 2640
SR 2640
CAS#105350-26-3 (free base)

Theoretical Analysis

MedKoo Cat#: 128814

Name: SR 2640

CAS#: 105350-26-3 (free base)

Chemical Formula: C23H18N2O3

Exact Mass: 370.1317

Molecular Weight: 370.41

Elemental Analysis: C, 74.58; H, 4.90; N, 7.56; O, 12.96

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
25mg USD 1,150.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
SR 2640; SR2640; SR-2640
IUPAC/Chemical Name
2-((3-(quinolin-2-ylmethoxy)phenyl)amino)benzoic acid
InChi Key
LMPZHLXYBWGGNT-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H18N2O3/c26-23(27)20-9-2-4-11-22(20)24-17-7-5-8-19(14-17)28-15-18-13-12-16-6-1-3-10-21(16)25-18/h1-14,24H,15H2,(H,26,27)
SMILES Code
O=C(C1=C(NC2=CC(OCC3=NC4=C(C=C3)C=CC=C4)=CC=C2)C=CC=C1)O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 370.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Di Capite J, Shirley A, Nelson C, Bates G, Parekh AB. Intercellular Ca2+ wave propagation involving positive feedback between CRAC channels and cysteinyl leukotrienes. FASEB J. 2009 Mar;23(3):894-905. doi: 10.1096/fj.08-118935. Epub 2008 Oct 31. PubMed PMID: 18978154. 2: Chiba Y, Oshita M, Sakai H, Misawa M. Involvements of cysteinyl leukotrienes and nitric oxide in antigen-induced venodilatation of nasal mucosa in sensitized rats in vivo. J Smooth Muscle Res. 2007 Aug;43(4):139-44. PubMed PMID: 17928747. 3: Pons L, Droy-Lefaix MT, Bueno L. Leukotriene D4 participates in colonic transit disturbances induced by intracolonic administration of trinitrobenzene sulfonic acid in rats. Gastroenterology. 1992 Jan;102(1):149-56. PubMed PMID: 1727747. 4: Frølund L, Madsen F, Nielsen J. Reproducibility of leukotriene D4 inhalation challenge in asthmatics. Effect of a novel leukotriene D4/E4-antagonist (SR 2640) on leukotriene D4-induced bronchoconstriction. Allergy. 1991 Jul;46(5):355-61. PubMed PMID: 1928658. 5: Rhaleb NE, Rouissi N, Drapeau G, Jukic D, Regoli D. Characterization of bradykinin receptors in peripheral organs. Can J Physiol Pharmacol. 1991 Jul;69(7):938-43. PubMed PMID: 1720068. 6: Nielsen OH, Ahnfelt-Rønne I, Thomsen MK, Kissmeyer AM, Langholz E. Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4. PubMed PMID: 1677467. 7: Christensen A, Kissmeyer AM, Eilertsen E, Rastrup-Andersen N, Ahnfelt-Rønne I. Pharmacokinetics and metabolism of a leukotriene D4/E4-antagonist (2-[3'-(2"-quinolylmethoxy)phenylamino]benzoic acid) in rat, dog,guinea pig and man. Xenobiotica. 1990 Apr;20(4):417-34. PubMed PMID: 2161166. 8: Bouchelouche PN, Ahnfelt-Rønne I, Thomsen MK. LTD4 increases cytosolic free calcium and inositol phosphates in human neutrophils: inhibition by the novel LTD4 receptor antagonist, SR2640, and possible relation to modulation of chemotaxis. Agents Actions. 1990 Mar;29(3-4):299-307. PubMed PMID: 2160189. 9: Kirstein D, Rachlin S, Ahnfelt-Rønne I. The leukotriene D4/E4 antagonist SR2640: recent results with smooth muscle preparations. Agents Actions. 1990 Jan;29(1-2):74-6. PubMed PMID: 2158223. 10: Thomsen MK, Ahnfelt-Rønne I. Inhibition by the LTD4 antagonist, SR2640, of effects of LTD4 on canine polymorphonuclear leukocyte functions. Biochem Pharmacol. 1989 Jul 15;38(14):2291-5. PubMed PMID: 2546563. 11: Ahnfelt-Rønne I, Kirstein D, Kaergaard-Nielsen C. SR2640 (2-[3-(2-quinolylmethoxy)phenylamino]benzoic acid): a novel leukotriene antagonist. Agents Actions. 1989 Jan;26(1-2):82-3. PubMed PMID: 2540647. 12: Ahnfelt-Rønne I, Kirstein D, Kaergaard-Nielsen C. A novel leukotriene D4/E4 antagonist, SR2640 (2-[3-(2-quinolylmethoxy)phenylamino]benzoic acid). Eur J Pharmacol. 1988 Oct 11;155(1-2):117-28. PubMed PMID: 2854067.